Key Developments: RTI Biologics Inc (RTIX.O)
4.33USD
17 May 2013
$-0.05 (-1.14%)
$4.38
$4.41
$4.41
$4.30
304,104
272,379
$5.11
$3.35
Latest Key Developments (Source: Significant Developments)
RTI Biologics Inc Raises Low End Of Prior FY 2013 Revenue Guidance To A Range Above Analysts' Estimates; Reaffirms FY 2013 EPS Guidance; Issues Q2 2013 Guidance In Line With Analysts' Estimates
RTI Biologics Inc announced that for fiscal 2013, it expects revenues to be between $179-$182 million, net income per fully diluted share to be in the range of $0.17 to $0.19. For the second quarter of 2013, the Company expects revenues to be between $42 million and $43 million, and net income per fully diluted share to be approximately $0.03. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $178 million and EPS of $0.17 for fiscal 2013; revenue of $43 million and EPS of $0.03 for the second quarter of 2013. Full Article
RTI Biologics Inc Announces Positive Clinical Results For BioCleanse-Processed BTB Allografts Used In ACL Reconstruction
RTI Biologics Inc announced the results of a recent randomized prospective clinical study of BioCleanse-processed bone-patellar tendon-bone (BTB) allografts used in anterior cruciate ligament (ACL) reconstruction surgery. The study was published in the peer reviewed journal, Knee Surgery, Sports Traumatology, Arthroscopy, in December 2012. The article compares the clinical outcomes of BTB allografts processed using RTI`s patented BioCleanse Tissue Sterilization Process with a control group consisting of aseptically-processed allografts from the three U.S. tissue banks that provide this type of allograft. According to the American Association of Tissue Banks` 13th edition of Standards for Tissue Banking, aseptic processing refers to the processing of tissue using methods to prevent, restrict or minimize contamination with microorganisms from the environment, processing personnel, and/or equipment. A total of 67 patients undergoing ACL reconstruction at six independent investigation sites were evaluated at six, 12 and 24 months. After randomization, 24 patients received aseptic BTB allografts and 43 patients received BioCleanse-sterilized allografts. According to Millennium Research Group`s U.S. Markets for Orthopedic Soft Tissue Solutions 2011" report, more than 457,400 ACL reconstructions are performed annually in the U.S., with 21% of those using allograft implants. Full Article
RTI Biologics Inc Receives 510(k) Clearance For Porcine Dermis Implant
RTI Biologics Inc announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for porcine dermis implant. The implant is intended for use in soft tissue repair procedures such as hernia repair. Stored hydrated and ready-to-use, the porcine dermis implant is comprised of non-crosslinked porcine dermis, designed to act as a scaffold that allows for neovascularization and reincorporation with the patient`s own tissue. The implants will be made available in various shapes and sizes. The implants will be processed at RTI`s facility in Neunkirchen, Germany for commercial distribution in the U.S. later this year. The facility has been validated for processing and has begun production of the implants. Full Article
RTI Biologics Inc Issues FY, Q1 2013 Guidance Below Analysts' Estimates
RTI Biologics Inc announced that for fiscal 2013, it expects revenues to be between $178-$182 million, net income per fully diluted share to be in the range of $0.17 to $0.19. For the first quarter of 2013, the Company expects revenues to be between $38 million and $39 million, and net income per fully diluted share to be approximately $0.02. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $189 million and EPS of $0.22 for fiscal 2013; revenue of $46 million and EPS of $0.05 for the first quarter of 2013. Full Article
RTI Biologics Inc Narrows FY 2012 Revenue Outlook To A Range In Line With Analysts' Estimates; Revises FY 2012 EPS Outlook To A Range Below Analysts' Estimates; Issues Q4 2012 Outlook Below Estimates
RTI Biologics Inc announced that for fiscal 2012, it expects revenue to be between $178-$179 million and net income per fully diluted share for 2012 to be approximately $0.15. Excluding a pre-tax litigation settlement charge of $2.35 million taken in the second quarter of 2012, or $0.03 per fully diluted share, the Company expects full year net income per fully diluted share for 2012 to be approximately $0.18, based on 56.1 million shares outstanding. For the fourth quarter of 2012, the Company expects revenues to be between $44-$45 million, and net income per fully diluted share to be $0.04. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $179 million and EPS of $0.18 for fiscal 2012; revenue of $46 million and EPS of $0.05 for the fourth quarter of 2012. Full Article
RTI Biologics Inc Raises FY 2012 Guidance; Issues Q3 2012 Guidance; Revenue Guidance Above Analysts' Estimates
RTI Biologics Inc announced that as a result of first half 2012 results that exceeded expectations and better visibility into second half 2012 trends, the Company has raised fiscal 2012 revenues guidance and now expects revenues to be between $177 million to $179 million, as compared to prior guidance of $176 million to $178 million. As a result of the litigation settlement charge of $0.03 per fully diluted share taken in the second quarter 2012, fiscal 2012 net income per fully diluted share (EPS) is now expected to be in the range of $0.14 to $0.15, as compared to prior guidance of $0.16 to $0.17 per fully diluted share. For the third quarter of 2012, the Company expects revenues to be between $44 million and $45 million and net income per fully diluted share to be approximately $0.04. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $177 million and EPS of $0.17 for fiscal 2012; and revenue of $43 million and EPS of $0.04 for the third quarter of 2012. Full Article
RTI Biologics Inc Raises FY 2012 Revenue Guidance; Raises Low End Of Prior FY 2012 EPS Guidance To A Range In Line With Analysts' Estimates; Issues Q2 2012 Guidance In Line With Analysts' Estimates
RTI Biologics Inc announced that as a result of better than expected results in the first quarter, the Company is raising its fiscal 2012 revenue guidance. The Company now expects revenues for fiscal 2012 to be between $176 million and $178 million, as compared to prior guidance of between $174 million and $176 million. Fiscal 2012 net income is expected to be between $0.16 and $0.17 per fully diluted share (EPS), as compared to its prior guidance of between $0.15 and $0.17 per fully diluted share. For the second quarter of 2012, the Company expects revenues to be between $43 million and $44 million, and net income per fully diluted share to be approximately $0.04. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $176 million and EPS of $0.16 for fiscal 2012; and revenue of $44 million and EPS of $0.04 for the second quarter of 2012. Full Article
RTI Biologics Inc Issues Q1 2012 Guidance In Line With Analysts' Estimates; Issues FY 2012 Guidance; EPS Guidance Below Analysts' Estimates
RTI Biologics Inc announced that for first quarter of 2012, it expects revenues to be between $41 million and $42 million, and net income per fully diluted share to be approximately $0.03. For fiscal 2012, it expects revenue to be in the range of $174 million and $176 million. Net income per fully diluted share is expected to be in the range of $0.15 to $0.17, based on 55.8 million fully diluted shares outstanding. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $42 million and EPS of $0.04 for first quarter of 2012; revenue of $176 million and EPS of $0.18 for fiscal 2012. Full Article
RTI Biologics Inc Raises FY 2011 Revenue Guidance; Sees FY 2011 EPS Guidance At High End Of Prior Range; Issues Q4 2011 Guidance In Line With Analysts' Estimates
RTI Biologics Inc announced that it has raised fiscal 2011 revenue guidance. The Company now expects revenues to be between $166 million and $167 million for fiscal 2011, as compared to prior guidance of between $164 million and $166 million and net income to be approximately $0.14 per fully diluted share, at the top end of prior guidance of between $0.12 and $0.14 per fully diluted share. For the fourth quarter of 2011, the Company expects revenues to be between $40 million and $41 million, and net income per fully diluted share to be approximately $0.03. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $41 million and EPS of $0.04 for fourth quarter of 2011; revenue of $166 million and EPS of $0.13 for fiscal 2011. Full Article
RTI Biologics Inc Issues Q3 2011 Guidance; Revenue Guidance Above Analysts' Estimates; Raises FY 2011 Guidance
RTI Biologics Inc announced that for third quarter of 2011, it expects revenues to be between $40 million to $41 million, and net income per fully diluted share to be approximately $0.03. The Company raised fiscal 2011 revenue and earnings per share (EPS) guidance. The Company now expects revenues for fiscal 2011 to be between $164 million to $166 million, as compared to prior guidance of $159 million to $162 million. Net income per fully diluted share are now expected to be in the range of $0.12 to $0.14, based on 55.4 million shares outstanding, as compared to prior guidance of $0.11 to $0.13 per fully diluted share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $39 million and EPS of $0.03 for third quarter of 2011; revenue of $162 million and EPS of $0.12 for fiscal 2011. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
